Induction and maintenance of monocyte cytotoxicity during treatment with liposomes containing muramyl tripeptide despite tachyphylaxis to the cytokine response

E. Galligioni, D. Favaro, M. Santarosa, M. Quaia, A. Spada, A. Freschi, D. Alberti

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Monocyte-mediated cytotoxicity (determined in a 72-h 111In release assay) and the circulating levels of tumor necrosis factor α (TNF-α) interleukin (IL) 1β, IL-6, IFN-γ, C-reactive protein, and β2-microglobulin were determined in 14 melanoma patients treated with multilamellar vesicle liposomes containing muramyl tripeptide phosphatidylethanolamine, 4 mg twice a week for 12 weeks. Monocyte-mediated cytotoxicity increased 24 h after the first infusion in 9 of 14 patients and had reached maximum levels (mean, 44% ± 8) in all patients by the sixth week; similar values were observed at the 12th week. Once increased in vivo, peripheral blood monocyte cytotoxicity was not susceptible to any further increase after a subsequent in vitro incubation of the monocytes with liposomes, However, the peripheral blood monocytes which were not cytotoxic in vivo were activated by in vitro incubation with liposomes and not by medium. TNF-α and IL-6 peaked 2 h after the first infusion and returned to baseline values at 24 h; they were not significantly increased by subsequent treatments. The induction of fever in patients, observed 2 h after the first infusion, correlated with TNF-α and IL-6 levels. Similarly, C-reactive protein levels also increased at 24 h, but only after the first dose, No increase in β2-microglobulin and IL-1β levels was observed, and IFN-γ was never detected in serum. Two patients experienced stable disease lasting 7 and 12 months, and 12 patients progressed. These results show that multilamellar vesicle muramyl tripeptide phosphatidylethanolamine administration activates monocyte cytotoxicity and cytokine production (TNF-α, IL-6). Chronic treatment with multilamellar vesicle muramyl tripeptide phosphatidylethanolamine results in tachyphylaxis in terms of cytokine secretion but not cytotoxicity. There was no difference between the maximum cytotoxicity levels obtained in vivo and those obtained in vitro using the same agent. A better understanding of immunoregulation is required for a rational application of this and related immunotherapies.

Original languageEnglish
Pages (from-to)493-499
Number of pages7
JournalClinical Cancer Research
Volume1
Issue number5
Publication statusPublished - 1995

Fingerprint

Tachyphylaxis
Liposomes
Monocytes
Maintenance
Cytokines
Interleukin-6
Tumor Necrosis Factor-alpha
Interleukin-1
C-Reactive Protein
Therapeutics
Immunotherapy
Melanoma
Fever
Serum
In Vitro Techniques
mifamurtide

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Induction and maintenance of monocyte cytotoxicity during treatment with liposomes containing muramyl tripeptide despite tachyphylaxis to the cytokine response. / Galligioni, E.; Favaro, D.; Santarosa, M.; Quaia, M.; Spada, A.; Freschi, A.; Alberti, D.

In: Clinical Cancer Research, Vol. 1, No. 5, 1995, p. 493-499.

Research output: Contribution to journalArticle

Galligioni, E, Favaro, D, Santarosa, M, Quaia, M, Spada, A, Freschi, A & Alberti, D 1995, 'Induction and maintenance of monocyte cytotoxicity during treatment with liposomes containing muramyl tripeptide despite tachyphylaxis to the cytokine response', Clinical Cancer Research, vol. 1, no. 5, pp. 493-499.
Galligioni, E. ; Favaro, D. ; Santarosa, M. ; Quaia, M. ; Spada, A. ; Freschi, A. ; Alberti, D. / Induction and maintenance of monocyte cytotoxicity during treatment with liposomes containing muramyl tripeptide despite tachyphylaxis to the cytokine response. In: Clinical Cancer Research. 1995 ; Vol. 1, No. 5. pp. 493-499.
@article{b3fe67b60555408594ad705c17156965,
title = "Induction and maintenance of monocyte cytotoxicity during treatment with liposomes containing muramyl tripeptide despite tachyphylaxis to the cytokine response",
abstract = "Monocyte-mediated cytotoxicity (determined in a 72-h 111In release assay) and the circulating levels of tumor necrosis factor α (TNF-α) interleukin (IL) 1β, IL-6, IFN-γ, C-reactive protein, and β2-microglobulin were determined in 14 melanoma patients treated with multilamellar vesicle liposomes containing muramyl tripeptide phosphatidylethanolamine, 4 mg twice a week for 12 weeks. Monocyte-mediated cytotoxicity increased 24 h after the first infusion in 9 of 14 patients and had reached maximum levels (mean, 44{\%} ± 8) in all patients by the sixth week; similar values were observed at the 12th week. Once increased in vivo, peripheral blood monocyte cytotoxicity was not susceptible to any further increase after a subsequent in vitro incubation of the monocytes with liposomes, However, the peripheral blood monocytes which were not cytotoxic in vivo were activated by in vitro incubation with liposomes and not by medium. TNF-α and IL-6 peaked 2 h after the first infusion and returned to baseline values at 24 h; they were not significantly increased by subsequent treatments. The induction of fever in patients, observed 2 h after the first infusion, correlated with TNF-α and IL-6 levels. Similarly, C-reactive protein levels also increased at 24 h, but only after the first dose, No increase in β2-microglobulin and IL-1β levels was observed, and IFN-γ was never detected in serum. Two patients experienced stable disease lasting 7 and 12 months, and 12 patients progressed. These results show that multilamellar vesicle muramyl tripeptide phosphatidylethanolamine administration activates monocyte cytotoxicity and cytokine production (TNF-α, IL-6). Chronic treatment with multilamellar vesicle muramyl tripeptide phosphatidylethanolamine results in tachyphylaxis in terms of cytokine secretion but not cytotoxicity. There was no difference between the maximum cytotoxicity levels obtained in vivo and those obtained in vitro using the same agent. A better understanding of immunoregulation is required for a rational application of this and related immunotherapies.",
author = "E. Galligioni and D. Favaro and M. Santarosa and M. Quaia and A. Spada and A. Freschi and D. Alberti",
year = "1995",
language = "English",
volume = "1",
pages = "493--499",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "5",

}

TY - JOUR

T1 - Induction and maintenance of monocyte cytotoxicity during treatment with liposomes containing muramyl tripeptide despite tachyphylaxis to the cytokine response

AU - Galligioni, E.

AU - Favaro, D.

AU - Santarosa, M.

AU - Quaia, M.

AU - Spada, A.

AU - Freschi, A.

AU - Alberti, D.

PY - 1995

Y1 - 1995

N2 - Monocyte-mediated cytotoxicity (determined in a 72-h 111In release assay) and the circulating levels of tumor necrosis factor α (TNF-α) interleukin (IL) 1β, IL-6, IFN-γ, C-reactive protein, and β2-microglobulin were determined in 14 melanoma patients treated with multilamellar vesicle liposomes containing muramyl tripeptide phosphatidylethanolamine, 4 mg twice a week for 12 weeks. Monocyte-mediated cytotoxicity increased 24 h after the first infusion in 9 of 14 patients and had reached maximum levels (mean, 44% ± 8) in all patients by the sixth week; similar values were observed at the 12th week. Once increased in vivo, peripheral blood monocyte cytotoxicity was not susceptible to any further increase after a subsequent in vitro incubation of the monocytes with liposomes, However, the peripheral blood monocytes which were not cytotoxic in vivo were activated by in vitro incubation with liposomes and not by medium. TNF-α and IL-6 peaked 2 h after the first infusion and returned to baseline values at 24 h; they were not significantly increased by subsequent treatments. The induction of fever in patients, observed 2 h after the first infusion, correlated with TNF-α and IL-6 levels. Similarly, C-reactive protein levels also increased at 24 h, but only after the first dose, No increase in β2-microglobulin and IL-1β levels was observed, and IFN-γ was never detected in serum. Two patients experienced stable disease lasting 7 and 12 months, and 12 patients progressed. These results show that multilamellar vesicle muramyl tripeptide phosphatidylethanolamine administration activates monocyte cytotoxicity and cytokine production (TNF-α, IL-6). Chronic treatment with multilamellar vesicle muramyl tripeptide phosphatidylethanolamine results in tachyphylaxis in terms of cytokine secretion but not cytotoxicity. There was no difference between the maximum cytotoxicity levels obtained in vivo and those obtained in vitro using the same agent. A better understanding of immunoregulation is required for a rational application of this and related immunotherapies.

AB - Monocyte-mediated cytotoxicity (determined in a 72-h 111In release assay) and the circulating levels of tumor necrosis factor α (TNF-α) interleukin (IL) 1β, IL-6, IFN-γ, C-reactive protein, and β2-microglobulin were determined in 14 melanoma patients treated with multilamellar vesicle liposomes containing muramyl tripeptide phosphatidylethanolamine, 4 mg twice a week for 12 weeks. Monocyte-mediated cytotoxicity increased 24 h after the first infusion in 9 of 14 patients and had reached maximum levels (mean, 44% ± 8) in all patients by the sixth week; similar values were observed at the 12th week. Once increased in vivo, peripheral blood monocyte cytotoxicity was not susceptible to any further increase after a subsequent in vitro incubation of the monocytes with liposomes, However, the peripheral blood monocytes which were not cytotoxic in vivo were activated by in vitro incubation with liposomes and not by medium. TNF-α and IL-6 peaked 2 h after the first infusion and returned to baseline values at 24 h; they were not significantly increased by subsequent treatments. The induction of fever in patients, observed 2 h after the first infusion, correlated with TNF-α and IL-6 levels. Similarly, C-reactive protein levels also increased at 24 h, but only after the first dose, No increase in β2-microglobulin and IL-1β levels was observed, and IFN-γ was never detected in serum. Two patients experienced stable disease lasting 7 and 12 months, and 12 patients progressed. These results show that multilamellar vesicle muramyl tripeptide phosphatidylethanolamine administration activates monocyte cytotoxicity and cytokine production (TNF-α, IL-6). Chronic treatment with multilamellar vesicle muramyl tripeptide phosphatidylethanolamine results in tachyphylaxis in terms of cytokine secretion but not cytotoxicity. There was no difference between the maximum cytotoxicity levels obtained in vivo and those obtained in vitro using the same agent. A better understanding of immunoregulation is required for a rational application of this and related immunotherapies.

UR - http://www.scopus.com/inward/record.url?scp=0029047127&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029047127&partnerID=8YFLogxK

M3 - Article

VL - 1

SP - 493

EP - 499

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 5

ER -